Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS).

Diamant ThaҫiAndreas PinterMichael SebastianChritsian TermeerMichael SticherlingSascha GerdesKnut SchäkelSven WegnerStefanie KrampeHolger BartzChristian RauschFriedemann TautKilian Eyerich

Published in: The British journal of dermatology (2023)

In these exploratory analyses, guselkumab, as a first-line systemic treatment or second-line systemic treatment in FAE non-responders, was associated with long-term clinical efficacy up to Week 100, including a withdrawal period.

Keyphrases

clinical trial
end stage renal disease
study protocol
chronic kidney disease
ejection fraction
open label
combination therapy
phase ii
phase iii